-
Your selected country is
Japan
- Change country/language
-
抗体試薬
- フローサイトメトリー用試薬
-
ウェスタンブロッティング抗体試薬
- イムノアッセイ試薬
-
シングルセル試薬
- BD® AbSeq Assay | シングルセル試薬
- BD Rhapsody™ Accessory Kits | シングルセル試薬
- BD® Single-Cell Multiplexing Kit | シングルセル試薬
- BD Rhapsody™ Targeted mRNA Kits | シングルセル試薬
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit | シングルセル試薬
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
-
細胞機能評価のための試薬
-
顕微鏡・イメージング用試薬
-
細胞調製・分離試薬
-
- BD® AbSeq Assay | シングルセル試薬
- BD Rhapsody™ Accessory Kits | シングルセル試薬
- BD® Single-Cell Multiplexing Kit | シングルセル試薬
- BD Rhapsody™ Targeted mRNA Kits | シングルセル試薬
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit | シングルセル試薬
- BD® OMICS-Guard Sample Preservation Buffer
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- Japan (Japanese)
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD™ Stem Cell Control CD34+ Whole Blood Process Control
(RUO (GMP))
Regulatory Statusの凡例
Becton, Dickinson and Companyの書面による明示的な許諾を得た使用以外での製品の使用は固く禁じられています。
説明
The BD™ Stem Cell control is intended as a complete, two-level, process control for immunophenotyping and enumeration of leucocytes by flow cytometry. It is a control for antibody staining, red blood cell (RBC) lysis, instrument setup and performance, and data analysis.
調製と保管
• Store vials upright, tightly capped, at 2°C to 8°C when not in use.
• Unopened vials are stable until the expiration date indicated on each vial and assay sheet.
• Opened vials are stable for 12 thermal cycles (uses) when handled properly. A thermal cycle constitutes performing all steps under Section 5, Instructions for Use, once.
• Avoid unnecessary cycles of warming and cooling. Protect this product from freezing, from temperatures above 30°C, and from prolonged time at room temperature (18°C to 26°C). Follow exactly the steps in Section 5 Instructions For Use.
説明 | 数量/容量 | Part Number | EntrezGene ID |
---|---|---|---|
CD34+ Low (approx. 10 cells/µl) | 2 mL (1 ea) | 340991-02 | N/A |
CD34+ High (approx. 35 cells/µl) | 2 mL (1 ea) | 340991-01 | N/A |
開発者向け参考資料 (8)
-
Centers for Disease Control. Revised Guidelines for the Performance of CD4+ T-Cell Determinations in Persons with HIV Infection. MMWR. 1994; 43:1-21. (Biology).
-
Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. NCCLS document H42-A. 1998. (Biology).
-
Gratama JW, Orfao A, Barnett D, et al. Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. Cytometry. 1998; 34:128–142. (Biology).
-
Marti G, Johnsen H, Sutherland R, Serke S. Letter to the Editor: A convergence of methods for a worldwide standard for CD34+ cell enumeration. J Hematotherapy. 1998; 7:105-109. (Biology).
-
Statistical Quality Control for Quantitative Measurements: Principles and Definitions; Approved Guideline. NCCLS document C-24A2. 1999. (Biology).
-
Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
-
Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematotherapy. 1996; 5:213-226. (Biology).
-
Villanova, PA: National Committee for Clinical Laboratory Standards; Clinical Applications of Flow Cytometry: Immunophenotyping of Leukemic Cells; Approved Guideline. H43-A. 1998. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.